PharmaEssentia: Q2 2026 revenue rose 90% YoY, net income jumped 204%, and EPS hit a record NT$6.13
Lesedauer weniger als 1 min
Q2 2026 saw revenue surge 90% YoY to NT$6.86B, with net income up 204% and EPS at a record NT$6.13. Gross and operating margins improved significantly, driven by global expansion of ROPEG and a robust pipeline targeting new indications and markets.
Original document: PharmaEssentia Corp. [6446] Slides Release — Aug. 12 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr